Possibility of PMX-DHP therapy as a principal strategy against cytokine storm in COVID-19: Insights from reconstructed coagulation data.

Ogawa, Haruhiko; Kakuchi, Yasushi; Asakura, Hidesaku

Ogawa, Haruhiko; Kakuchi, Yasushi; Asakura, Hidesaku.

Ogawa H; Department of Environmental and Preventive Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan.
Kakuchi Y; Division of Nephrology, Department of Internal Medicine, Rakuwakai Otowakinen Hospital, Kyoto, Japan.
Asakura H; Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.

J Clin Apher ; 36(5): 785-786, 2021 Oct.

Article in English | MEDLINE | ID: covidwho-1305128

Subject(s)

Anti-Bacterial Agents/administration & dosage; COVID-19/complications; Cytokine Release Syndrome/drug therapy; Hemoperfusion/methods; Polymyxin B/administration & dosage; SARS-CoV-2; Blood Coagulation; COVID-19/immunology; Fibrin Fibrinogen Degradation Products/analysis; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Polymyxin B / Hemoperfusion / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Anti-Bacterial Agents Topics: Long Covid Limits: Humans Language: English Journal: J Clin Apher Year: 2021 Document Type: Article Affiliation country: Jca.21925

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google